TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00998361

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hemopoietic stem cell transplant
Description: administration of 15 mg/kg of thiotepa + 140 mg/sqm of melphalan followed by infusion of allogeneic hemopoietic stem cell
Study: NCT04631250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic Acid-Containing Product in Cutaneous Dose Form
Description: 5-Aminolevulinic Acid was applied to both sides of the face.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic Acid-Containing Product in Cutaneous Dose Form
Description: 5-Aminolevulinic Acid was applied to both sides of the face.
Study: NCT02057250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Solution Route of administration: Subcutaneous

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-Injector Device (AID)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto-Injector Device (AID)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled Syringe (PFS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled Syringe (PFS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Dispensed according to local practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Dispensed according to local practice.
Study: NCT05204277

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalescence™ boost™ PF 40%
Description: 40% hydrogen peroxide in-office bleaching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalescence™ boost™ PF 40%
Description: 40% hydrogen peroxide in-office bleaching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalescence™ boost™ PF 40%
Description: 40% hydrogen peroxide in-office bleaching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalescence™ boost™ PF 40%
Description: 40% hydrogen peroxide in-office bleaching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalustre™
Description: 6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalustre™
Description: 6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalustre™
Description: 6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opalustre™
Description: 6.6% hydrochloric acid and silicon carbide microparticles microabrasion paste

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI-Paste Plus®
Description: casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI-Paste Plus®
Description: casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI-Paste Plus®
Description: casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI-Paste Plus®
Description: casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP) remineralizing tooth crème
Study: NCT01635296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045377
Description: Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5045377
Description: Multiple escalating oral doses, Days 1 to 5 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 20 mg/m2 sc, Days 1 to 10 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 1 gm/m2 iv, Days 1 to 6 of each 28-day cycle
Study: NCT04240496

Intervention type: OTHER
Group type: OTHER
Intervention: Determination of plasma concentration of clozapine/ Genotyping
Description: Determination of trough plasma concentration of clozapine (C0) Genotyping of CYP1A2 \& CYP2C19
Study: NCT01662102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin
Description: Zevalin administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered intravenously.
Study: NCT00417417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: Lyophilized rilonacept will be supplied by Regeneron Pharmaceuticals at 160 mg/vial and reconstituted with 2.3 mL of sterile water for injection by the Clinical Center Pharmacy Intravenous Admixture Unit. The formulation contains 80 mg/mL rilonacept, histidine, citrate, PEG 3350, polysorbate 20, glycine, arginine, and sucrose (pH 6.5). Matching placebo in the identical formulation will also be supplied, and also reconstituted with 2.3 mL of sterile water for injection. Each administration of study drug will consist of two syringes containing 2.0 mL in each syringe (320 mg total drug).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Normal saline subcutaneously at each treatment visit.
Study: NCT01749332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perihepatic Phlebotomy
Study: NCT02625857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64041809 (Cohort 1A and 1B)
Description: JNJ-64041809 will be administered IV at a lower dose in Cohort 1A (1x10\^8 colony forming units \[CFU\]) and at a higher dose in Cohort 1B (1x10\^9 CFU).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64041809 (Cohort 2A and 2B)
Description: JNJ-64041809 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
Study: NCT02863419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral semaglutide once-daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Subcutaneous (s.c.) injection once-daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo once-daily.
Study: NCT01929746

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 subcutaneous injection
Description: participants will be randomized to receive a single subcutaneous injection of BIIB019, 75 mg or 150 mg per dose group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIIB019 subcutaneous injection
Description: participants will be randomized to receive a single subcutaneous injection of BIIB019, 75 mg or 150 mg per dose group
Study: NCT05021978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: 20 and 40 mg PRAX-944
Description: Once daily oral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: 120 mg PRAX-944
Description: Once daily oral treatment with titration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Part B: 120 mg PRAX-944 and Placebo
Description: Once daily oral treatment with titration followed by placebo
Study: NCT01048619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: In Part I, the bioavailability and tolerability of ON 01910.Na as single, oral, escalating doses in a fasting state (defined as no less than 30 min before next meal) is studied. Three patients get 70mg dose the 1st week. In the absence of drug-related grade 2 toxicity or higher, doses will escalate in each patient weekly (wk) to 140mg (wk 2), 280mg (wk 3), 560mg (wk 4) and 700mg (wk 5). At end of Part I all patients will be eligible for Part II. Part II proceeds if drug is measured in plasma and DLT not observed at 70mg dose in Part I. The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
Study: NCT03367988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Anesthesia
Description: Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Anesthesia will be induced with rocuronium, propofol, intravenous opioids, and other medication(s)/agent(s) at a concentration range/dose(s) based on the clinical need of the subject.~Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with IV opioids, propofol and/or medication(s)/agent(s), including inhalation anesthetic agents, at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid-free Anesthesia
Description: Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Acetaminophen 1g will be given prior to induction. Anesthesia will be induced with rocuronium 1mg, propofol 3-6 mg/kg, and succinylcholine 1.5 mg/kg Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready.
Study: NCT00043979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 Fluorodeoxyglucose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Lymphocyte cells are collected from a healthy donor by apheresis and infused into the patient with a central venous catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Induction - 750 mg/m\^2 intravenous (IV) infusion over 30 minutes x 1 dose. Day 5.~Transplant - 1200 mg/m\^2 per day IV infusion over 2 hours daily for 4 days; days -6, -5, -4, -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: 6 mg/kg per dose orally every other day (no day 9 dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Induction - 10 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 50 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Induction - 25 mg/m\^2 per day intravenous (IV) infusion over 30 minutes daily for 3 days. Days 1, 2, 3.~Transplant - 30 mg/m\^2 per day IV infusion over 30 minutes daily for 4 days; days -6, -5, -4, -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Transplant - 100 mg/m\^2 per day intravenous (IV) infusion over 15 minutes for 1 day; day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Induction - 60 mg/m\^2 per day in 2-4 divided doses by mouth daily for 5 days; days 1, 2, 3, 4, 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Initiated on day +3. Patients \>40kg, the initial dose will be 2 mg every 24 hours orally. Patients \<40 kg, the initial dose will be 1 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Day -1 at least 24 hours before the stem cell infusion at a dose of 0.03 mg/kg/day as a continuous infusion. Twelve hours later oral dose initiated at a dose of 0.1-0.15 mg/kg/day in two divided doses every 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Induction - 0.4 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days; 1, 2, 3, 4.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Stem cells from a healthy donor are collected and transplanted into the patient using a central venous catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell donation
Study: NCT04458870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Participants will receive 10 weekly individual acceptance and commitment therapy by a trained coach through zoom video-conferencing.
Study: NCT04069702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Blue
Description: VR Blue provides patients with an immersive computer-generated environment that can reduce pain, tension and distress.
Study: NCT06316050

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: humeral retroversion
Description: REVERSED SHOULDER ARTHROPLASTY IN TWO DIFFERENT GROUPS. Group 0 humeral retroversion, Group 30º humeral retroversion
Study: NCT01495403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: daily dosing
Study: NCT00930046

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine wound catheter
Description: 19 gauge fenestrated wound catheter inserted into the fascial planes of the surgical site prior to skin closure with a separate exit site.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline wound catheter
Description: 19 gauge fenestrated wound catheter will be inserted into the fascial planes of the surgical site prior to wound closure
Study: NCT02097264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0109-0012
Description: Solution for injection administered subcutaneously (s.c. - under the skin). 240 mg NNC0109-0012 will be administered weekly for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Solution for injection administered subcutaneously (s.c. - under the skin). Administered every other week for 12 weeks; Each active treatment involves 1 (one) s.c. injection of adalimumab 40 mg/0,8 mL solution for injection for paediatric use (Humira®)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Solution for injection administered subcutaneously (s.c. - under the skin).~1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Solution for injection administered subcutaneously (s.c. - under the skin).~1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks).
Study: NCT01549899

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person Cognitive Behavioral Therapy of Insomnia
Description: In-person CBTi was be provided by a master's or doctoral level mental health counselor (e.g., social worker or psychologist). This treatment consisted of 6-sessions and included the same efficacious and commonly used modules of CBTi (i.e., sleep education \& hygiene, stimulus control, progressive muscle relaxation, sleep restriction, and cognitive therapy).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Cognitive Behavioral Therapy of Insomnia
Description: The ICBTi treatment is an online protocol developed by the National Center for Telehealth and Technology, with the PI (DJT) as the subject matter expert. The treatment consists of the same components as the in-person CBTi, but their mode of delivery was considerably different due to the constraints of its automated, online format. Each of the six ICBTi sessions was divided into lessons covering different aspects of each of the components. The lessons were presented as audio recordings accompanied by visual graphics and animations. For several lessons, interactive components were included, such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
Study: NCT01755182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: approved pharmacologic therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: approved pharmacologic therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAE
Description: after randomization, and after 3 months
Study: NCT04572789

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids
Description: All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of omega-3 PUFAs intervention (EPA, 1.8 g/day) and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: omega-6 PUFAs
Description: All participants will complete a set of outcome measures at baseline and the follow-up visits before and after 12 weeks of placebo omega-6 PUFAs intervention and a series of blood tests for neurotransmitter, neurotrophic and neuroinflammation. The clinical efficacy and the peripheral blood biomarkers, will be analyzed at baseline and the end of the intervention.
Study: NCT04600596

Intervention type: BEHAVIORAL
Intervention: Recording of food intake.
Description: The food intake is recorded with a photographic food recognition mobile application. The total energy expenditure is recorded with the DLW method.

Intervention type: BEHAVIORAL
Intervention: Recording of food intake.
Description: The food intake is recorded with a photographic food recognition mobile application. The total energy expenditure is recorded with the DLW method.

Intervention type: BEHAVIORAL
Intervention: Recording of food intake.
Description: The food intake is recorded with a photographic food recognition mobile application. The total energy expenditure is recorded with the DLW method.
Study: NCT02130843

Intervention type: DEVICE
Intervention: INSERTION OF URETEHRL CATHETER
Description: USE OF A TIEMANN CATHETER TO INSERT THE URODYNAMIC STUDY CATHETER INTO THE BLADDER
Study: NCT01526577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC23-1306
Description: LC23-1306 10, 30, 100, 200, 400, 600 mg Placebo 10, 30, 100, 200, 400, 600 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: LC23-1306 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 90mg